Shattuck Labs (NASDAQ:STTK) Announces Earnings Results

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), FiscalAI reports.

Shattuck Labs Stock Performance

Shares of STTK stock traded up $0.28 during mid-day trading on Friday, reaching $4.76. 334,699 shares of the company’s stock traded hands, compared to its average volume of 967,788. Shattuck Labs has a 12 month low of $1.72 and a 12 month high of $8.33. The firm has a 50 day moving average price of $6.06 and a two-hundred day moving average price of $6.02. The firm has a market capitalization of $478.23 million, a PE ratio of -9.34 and a beta of 1.21.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on STTK. Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a research report on Friday, September 11th. JPMorgan Chase & Co. began coverage on Shattuck Labs in a research note on Friday, July 24th. They set an “overweight” rating and a $10.00 price objective for the company. Raymond James Financial reissued a “strong-buy” rating on shares of Shattuck Labs in a report on Thursday. Needham & Company LLC increased their target price on Shattuck Labs from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Finally, TD Cowen upgraded Shattuck Labs to a “strong-buy” rating in a report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $13.70.

Shattuck Labs Company Profile

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.